Triumvira Immunologics is a company that specializes in creating innovative immunotherapies. Founded in 2015 by Dr. Jonathan Bramson and Bloom Burton & Co., their mission is to develop safer and more effective treatments for cancer, including solid and liquid tumors, using their proprietary T cell Antigen Coupler (TAC) technology. This technology utilizes the entire natural T cell receptor and is not reliant on the major histocompatibility complex (MHC), allowing for the creation of therapies that can benefit a wider range of patients. Triumvira's goal is to revolutionize the field of immunotherapy and provide new hope to those battling various diseases, not just cancer.

Tags

Neoplasms

Digestive System Disorders

Immune System Diseases

Autologous CAR-T

T cell antigen coupler-T cells

Cell therapy

Disease domain score

A glimpse into the focused therapeutic areas

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

Disease Domain	Count

Neoplasms	8
Immune System Diseases	1
Endocrinology and Metabolic Disease	1
Hemic and Lymphatic Diseases	1

Top 5 Drug Type	Count

Autologous CAR-T	2
T cell antigen coupler-T cells	2
Cell therapy	1
Fusion protein	1
Universal CAR-T	1

Top 5 Target	Count

CLDN18.2(Claudin 18.2)	2
GC-C(Heat-stable enterotoxin receptor)	2
GPC3(Glypican-3)	1
CD19(B-lymphocyte antigen CD19)	1
ROR1(Inactive tyrosine-protein kinase transmembrane receptor ROR1)	1

Drugs associated with Triumvira Immunologics, Inc.

Pembrolizumab

Target

PD-1

Mechanism

PD-1 inhibitors

Active Org.

MSD KK

[+82]

Originator Org.

Merck & Co., Inc.

Active Indication

Malignant Pleural Mesothelioma [+553]

Inactive Indication

Adenocarcinoma, metastatic [+74]

Drug Highest PhaseApproved

First Approval Ctry. / Loc.

United States

First Approval Date04 Sep 2014

TAC-101 (Triumvira)

Target

CLDN18.2

Mechanism

CLDN18.2 inhibitors [+2]

Active Org.

Triumvira Immunologics, Inc.

Originator Org.

Triumvira Immunologics, Inc.

Active Indication

Metastatic Solid Tumor [+2]

Inactive Indication-

Drug Highest PhasePhase 1/2

First Approval Ctry. / Loc.-

First Approval Date-

TAC100-HER2

Target-

Mechanism-

Active Org.

Triumvira Immunologics, Inc.

Originator Org.

Triumvira Immunologics, Inc.

Active Indication

Neoplasms

Inactive Indication-

Drug Highest PhaseClinical

First Approval Ctry. / Loc.-

First Approval Date-

Clinical Trials associated with Triumvira Immunologics, Inc.

NCT05862324

/ Active, not recruitingPhase 1/2

A Phase 1/2 Study Investigating the Safety and Efficacy of Autologous TAC T Cells in Subjects With Unresectable, Locally Advanced or Metastatic Claudin 18.2+ Solid Tumors

TAC01-CLDN18.2 is a novel cell therapy that consists of genetically engineered autologous T cells expressing T-cell Antigen Coupler (TAC) that recognizes Claudin 18.2. TAC directs T-cells to the targeted antigen (CLDN 18.2), and once engaged with the target, activates them via the endogenous T cell receptor.
This is an open-label, multicenter Phase ½ study that aims to establish safety, maximum tolerated dose (MTD) or recommended Phase 2 dose (RP2D), pharmacokinetic profile and efficacy of TAC01-CLDN18.2.

Start Date23 Aug 2023

Sponsor / Collaborator

Triumvira Immunologics, Inc.

NCT04727151

/ TerminatedPhase 1/2

A Phase 1/2 Trial Investigating the Safety and Efficacy of Autologous TAC T Cell Monotherapy, and TAC T Cells in Combination With Pembrolizumab, in Relapsed HER2-Positive Solid Tumors

TAC01-HER2 is a novel cell therapy that consists of genetically engineered autologous T cells expressing T-cell Antigen Coupler (TAC) that recognizes human epidermal growth factor receptor 2 (HER2). TAC directs T-cells to the targeted antigen (HER2), and once engaged with the target, activates them via the endogenous T cell receptor.
This is an open-label, multicenter Phase 1/2 study that aims to establish safety, maximum tolerated dose (MTD) or recommended phase 2 dose (RP2D), pharmacokinetic profile and efficacy of TAC01-HER2 as a monotherapy, and in combination with pembrolizumab, in subjects with HER2 positive gastric and gastroesophageal adenocarcinoma.

Start Date19 Apr 2021

Sponsor / Collaborator

Triumvira Immunologics, Inc.

[+1]

NCT03880279

/ WithdrawnPhase 1/2

A Phase I/II Trial Investigating Safety and Efficacy of Autologous TAC T Cells Targeting CD19 in Relapsed or Refractory Large B-Cell Lymphoma

Phase I/II study to evaluate TAC01-CD19 in subjects with relapsed or refractory B-cell lymphomas. TAC technology is a novel way to genetically modify T cells and to redirect these T cells to target cancer antigens by co-opting the natural T cell receptor. The dose finding portion of this study will evaluate the safety and tolerability of increasing dose levels of TAC01-CD19 to identify a Maximal Tolerated Dose (MTD) or Recommended Phase II Dose (RP2D). The dose expansion portion of the study will further evaluate the safety, efficacy and pharmacokinetics of TAC01-CD19 at the RP2D.

Start Date01 May 2020

Sponsor / Collaborator

Triumvira Immunologics, Inc.

100 Clinical Results associated with Triumvira Immunologics, Inc.

0 Patents (Medical) associated with Triumvira Immunologics, Inc.

Literatures (Medical) associated with Triumvira Immunologics, Inc.

01 Feb 2025·Journal of Clinical Oncology

A phase 1/2 study evaluating the safety and efficacy of autologous TAC T cells in subjects with claudin 18.2+ advanced solid tumors.

Author: Dumbrava, Ecaterina Elena ; Sohal, Davendra ; Apostolopoulou, Maria ; Gavriliuc, Miriam ; Murugappan, Swaminathan ; Ku, Geoffrey Yuyat ; Schlechter, Benjamin L. ; Iqbal, Syma ; Moss, Kara M. ; Botta, Gregory P. ; Turcotte, Simon ; Giwa, Mobolaji ; Hosein, Peter Joel ; Saibil, Samuel

828Background: Claudin18.2 (CLDN18.2) is a tight junction protein found in gastric epithelial cells. It can become abnormally expressed in gastric cancer and other solid tumors, rendering it a candidate for targeted therapy. There are no approved therapeutic agents against CLDN18.2. The T cell antigen coupler (TAC) technology modifies T cells ex vivo , allowing cytotoxicity of tumor cells by co-opting the natural T cell receptor. TAC T cells demonstrate a safer profile than chimeric antigen receptor T cells. TAC01-CLDN18.2 is an autologous T-cell product comprising T cells expressing CLDN18.2 TAC. Methods: In this first-in-human study (NCT05862324), subjects will undergo leukapheresis and may receive bridging anticancer therapy during cell manufacturing. Prior to TAC01-CLDN18.2 infusion, subjects will undergo lymphodepletion chemotherapy. In Phase I, TAC01-CLDN18.2 will be administered at increasing doses (3 cohorts) in adult subjects with ≥2 lines of prior therapy (1 for subjects with pancreatic ductal adenocarcinoma (PDAC)) using the classic 3+3 dose escalation study design. CLDN18.2 expression levels will be determined centrally using a validated clinical trial assay. Dose-limiting toxicities (DLTs) will be assessed up to 28 days after the infusion. A second dose may be administered according to preidentified clinical and safety criteria. In Phase II, dose expansion groups will evaluate the efficacy, safety, and pharmacokinetics of the optimal TAC01-CLDN18.2 dose, with the option of redosing. Indications will include gastric and esophageal adenocarcinoma (group A), PDAC (group B) and ovarian and non-small cell lung cancer (group C) in subjects with <4 lines of prior therapy. Results: The first two dose cohorts of Phase I have been completed, with no reported dose-limiting toxicities (DLT). All of the TAC-related adverse events were low-grade. No cytokine release syndrome was reported. One subject in cohort 2 experienced a grade 1 neurotoxicity, which resolved the same day without intervention. Six subjects reported a total of 6 serious adverse events, none related to TAC01-CLDN18.2. An 83.3% disease control rate was observed at first tumor assessment (Day 29). One subject in cohort 1 with heavily pre-treated PDAC (3 prior lines) with high CLDN18.2 expression has an ongoing, confirmed partial response. The subject received a second dose and is still on treatment (6 months). Conclusions: Treatment with the lower doses of TAC01-CLDN18.2 is safe and shows promising clinical activity in a heavily pre-treated cancer population. Treatment of cohort 3 has begun. Clinical trial information: NCT05862324 .

09 Jan 2025·Cancer Immunology Research

Preclinical Development of T Cells Engineered to Express a T-Cell Antigen Coupler Targeting Claudin 18.2–Positive Solid Tumors

Article

Author: Sengupta, Sadhak ; Khan, Alima Naim ; Vucicevic, Andrea ; Nitya-Nootan, Thanyashanthi ; Prosser, Suzanna L. ; Benatar, Tania ; MacGregor, Heather ; Thakor, Gargi ; Lal, Prabha ; Wang, Ling ; Bader, Andreas G. ; Mathew, Princy ; Ip, Philbert ; Randhawa, Ritu R. ; Helsen, Christopher W. ; Xu, Stacey X. ; Hayes, Danielle L

AbstractThe T-cell antigen coupler (TAC) is a chimeric receptor that facilitates tumor antigen–specific activation of T cells by co-opting the endogenous T-cell receptor complex in the absence of tonic signaling. Previous data demonstrate that the TAC affords T cells with the ability to induce durable and safe antitumor responses in preclinical models of hematologic and solid tumors. In this study, we describe the preclinical pharmacology and safety of an autologous Claudin 18.2 (CLDN18.2)-directed TAC T-cell therapy, TAC01-CLDN18.2, in preparation for a phase I/II clinical study in subjects with CLDN18.2-positive solid tumors. Following a screen of putative TAC constructs, the specificity, activity, and cytotoxicity of TAC T cells expressing the final CLDN18.2-TAC receptor were evaluated in vitro and in vivo using gastric, gastroesophageal, and pancreatic tumor models as well as human cells derived from normal tissues. CLDN18.2-specific activity and cytotoxicity of CLDN18.2-TAC T cells were observed in coculture with various 2D tumor cultures naturally expressing CLDN18.2 as well as tumor spheroids. These effects occurred in models with low antigen levels and were positively associated with increasing CLDN18.2 expression. CLDN18.2-TAC T cells effectively eradicated established tumor xenografts in mice in the absence of observed off-target or on-target/off-tumor effects, elicited durable efficacy in recursive killing and tumor rechallenge experiments, and remained unreactive in coculture with human cells representing vital organs. Thus, the data demonstrate that CLDN18.2-TAC T cells can induce a specific and long-lasting antitumor response in various CLDN18.2-positive solid tumor models without notable TAC-dependent toxicities, supporting the clinical development of TAC01-CLDN18.2.

05 Apr 2024·Cancer Research

Abstract CT081: A phase 1/2 study investigating the safety and efficacy of autologous TAC T cells in subjects with unresectable, locally advanced, or metastatic claudin 18.2+ solid tumors

Author: Dumbrava, Ecaterina E. ; Saibil, Samuel ; Sohal, Davendra P. ; Moss, Kara ; Apostolopoulou, Maria ; Adib, Deyaa ; Schlecter, Ben ; Urgelles, Alejandro ; Iqbal, Syma ; Mueller, Amy ; Olson, Daniel

AbstractBackground: CLDN18.2 is a tight junction protein found in differentiated gastric epithelial cells, which can become abnormally or ectopically expressed in a number of solid tumor indications. This exposure profile illustrates the potential of CLDN18.2 as a candidate for targeted therapy. To date, there are no approved therapeutic agents directed against this target. The T cell antigen coupler (TAC) technology is an approach to modifying T cells ex vivo, which allows recognition and cytotoxicity of tumor cells by co-opting the natural T cell receptor. TAC T cells demonstrate a safer profile than chimeric antigen receptor T cells. TAC01-CLDN18.2 is an autologous T-cell product comprising T cells expressing CLDN18.2 TAC.Methods: This is a first-in-human study (NCT05862324) to investigate the safety and preliminary anti-tumor activity of TAC01-CLDN18.2 in CLDN18.2+/HER2- solid tumors. Subjects will undergo leukapheresis and may receive bridging anticancer therapy, if deemed necessary by the Investigator, during cell manufacturing. Prior to TAC01-CLDN18.2 infusion, subjects will undergo low-intensity lymphodepletion chemotherapy. In Phase I dose escalation, TAC01-CLDN18.2 will be administered at increasing doses (Cohorts 1-3) in adult subjects after ≥2 lines of therapy using the classic 3+3 dose escalation study design. Subjects with pancreatic ductal adenocarcinoma (PDAC) may have been treated with 1 line of prior therapy. CLDN18.2 expression levels will be determined centrally using a clinical trial assay validated across relevant indications. Dose limiting toxicities will be assessed up to 28 days from TAC01-CLDN18.2 infusion. A second dose may be administered, according to preidentified clinical and safety criteria. In Phase II, dose expansion groups will further evaluate the efficacy, safety, and pharmacokinetics of the optimal TAC01-CLDN18.2 dose, with the option of redosing. Indications will include gastric and esophageal adenocarcinoma (group A), PDAC (group B) and ovarian and non-small cell lung cancer (group C) in subjects after ≥2 and <4 lines of prior therapy (subjects with PDAC may have been exposed to 1 therapy). Definitions of eligible CLDN18.2 expression levels will be based on retrospective analysis of data from Phase 1 in association with clinical efficacy. A Simon 2-stage design will be used to enroll ≤57 subjects in Group A and ≤22 subjects in Group C. Group B will be exploratory and will enroll ≤10 subjects with an opportunity of cohort enrichment based on clinical efficacy data. The first patient was enrolled in December and continues to participate in the trial.Citation Format: Ecaterina E. Dumbrava, Daniel Olson, Samuel Saibil, Davendra P. Sohal, Syma Iqbal, Alejandro Urgelles, Maria Apostolopoulou, Amy Mueller, Kara Moss, Deyaa Adib, Ben Schlecter. A phase 1/2 study investigating the safety and efficacy of autologous TAC T cells in subjects with unresectable, locally advanced, or metastatic claudin 18.2+ solid tumors [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 2 (Late-Breaking, Clinical Trial, and Invited Abstracts); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(7_Suppl):Abstract nr CT081.

News (Medical) associated with Triumvira Immunologics, Inc.

12 Mar 2025

·www.prnewswire.com

Triumvira Immunologics to Present Updated Clinical Data at the 2025 SITC Spring Scientific, Cellular Therapy and Solid Tumors Conference

AUSTIN, Texas and HAMILTON, ON and SAN DIEGO, March 12, 2025 /PRNewswire/ -- Triumvira Immunologics, a clinical-stage company developing novel, targeted autologous and allogeneic T cell therapeutics that co-opt the natural biology of T cells to treat patients with solid tumors, today announced it will present at the 2025 SITC Spring Scientific, Cellular Therapy and Solid Tumors Conference in San Diego, California, from March 12-14, 2025. The poster presentation, titled "A Phase 1/2 Study on the Safety and Efficacy of Autologous TAC T Cells in Subjects with Claudin 18.2+ Advanced Solid Tumors," will provide a detailed overview of interim findings from the Phase 1/2 study (TACTIC-3 /NCT05862324). The TAC technology platform, demonstrated by TAC01-CLDN18.2, reprograms T cells to harness the natural T cell receptor (TCR) signaling complex, enabling precise tumor targeting while minimizing systemic toxicity compared to conventional engineered T cell therapies. "We are excited to share the latest clinical data from our ongoing TACTIC-3 study at the 2025 SITC Spring Scientific Conference. These interim findings further reinforce the potential of our TAC technology to deliver safe and effective cell therapies for patients with Claudin 18.2+ advanced solid tumors," said Robert Williamson, President of Triumvira Immunologics. "At Triumvira, we remain committed to pioneering innovative T cell therapies that harness the natural biology of T cells, offering new hope to patients with limited treatment options." Details of the abstract presentation are as follows: Abstract Number: 28 Abstract Title: A phase 1/2 study evaluating the safety and efficacy of autologous TAC T cells in subjects with claudin 18.2+ advanced solid tumors Authors: Ecaterina E. Dumbrava, Syma Iqbal, Simon Turcotte, Gregory Botta, Benjamin Schlechter, Geoffrey Ku, Peter Hosein, Sam Saibil, Miriam Gavriliuc, Maria Apostolopoulou, Mobolaji Giwa, Kara Moss, Swaminathan Murugappan, Davendra Sohal Date: Thursday, March 13, 2025, at 4:05 pm PDT About TACTIC-3 The TACTIC-3 trial ( NCT05862324) is a first-in-human Phase 1/2 study designed to evaluate the safety, recommended Phase II dose (RP2D), pharmacokinetics, and efficacy of TAC101-CLDN18.2 in patients with Claudin 18.2+ solid tumors who have undergone 2 or more lines of prior therapy (1 prior line in patients with pancreatic tumors). The trial includes subjects with advanced gastric and other solid tumors expressing Claudin 18.2, with the potential to address significant unmet medical needs in oncology. About Triumvira Immunologics Triumvira Immunologics, Inc. ("Triumvira") is a leading clinical-stage solid tumor cell therapy company developing unique, non-gene edited, first-in-class targeted autologous and allogeneic T cell therapeutics that co-opt the natural biology of T cells to treat patients with solid tumors. The company's proprietary T cell Antigen Coupler (TAC) technology platform activates natural T cell functions differently from other cell therapies such as CAR-T and engineered T cell receptor (TCR) therapies, resulting in clinically safe, effective, and re-dosable cell therapies. Triumvira is developing a pipeline targeting promising tumor-associated antigens such as Claudin 18.2, HER2, GUCY2C and GPC3. Triumvira has operations in San Diego, CA, Austin, Texas, and Hamilton, Ontario. For more information, visit us at or follow us on LinkedIn and X. Media Contact Ignacio Guerrero-Ros, Ph.D. Russo Partners 646-942-5604 [email protected] SOURCE Triumvira Immunologics WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

Cell TherapyImmunotherapy

28 Jan 2025

·pipelinereview.com

Triumvira Immunologics Presents Updated Clinical Data at the 2025 ASCO Gastrointestinal Cancers Symposium

AUSTIN, TX, USA and HAMILTON, Canada and SAN DIEGO, CA, USA I January 27, 2025 I Triumvira Immunologics , a clinical-stage company developing novel, targeted autologous and allogeneic T cell therapeutics that co-opt the natural biology of T cells to treat patients with solid tumors, recently presented an abstract at the 2025 American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium , which was held in San Francisco, California, from January 23-25, 2025. The company showcased updated clinical data from its ongoing Phase I/II TACTIC-3 study investigating the safety and efficacy of autologous TAC-T cells in subjects with Claudin 18.2+ advanced solid tumors (TACTIC-3 / NCT05862324 ). The poster presentation, titled “A Phase 1/2 Study Evaluating the Safety and Efficacy of Autologous TAC-T Cells in Subjects with Claudin 18.2+ Advanced Solid Tumors”, provided an in-depth look at interim results from the Phase I study. Key highlights included: The TAC technology platform, exemplified by TAC01-CLDN18.2, reprograms T cells to co-opt the natural T cell receptor (TCR) signaling complex, providing precise tumor targeting and reduced systemic toxicity compared to conventional engineered T cell therapies. About Triumvira Immunologics Triumvira Immunologics, Inc. (“Triumvira”) is a leading clinical-stage solid tumor cell therapy company developing unique, non-gene edited, first-in-class targeted autologous and allogeneic T cell therapeutics that co-opt the natural biology of T cells to treat patients with solid tumors. The company’s proprietary T cell Antigen Coupler (TAC) technology platform activates natural T cell functions differently from other cell therapies such as CAR-T and engineered T cell receptor (TCR) therapies, resulting in clinically safe, effective, and re-dosable cell therapies. Triumvira is developing a pipeline targeting promising tumor-associated antigens such as Claudin 18.2, HER2, GUCY2C and GPC3. Triumvira has operations in San Diego, CA, Austin, Texas, and Hamilton, Ontario. For more information, visit us at www.triumvira.com or follow us on LinkedIn and X . SOURCE: Triumvira Immunologics

ImmunotherapyASCOCell TherapyClinical Study

27 Jan 2025

·www.prnewswire.com

Triumvira Immunologics Presents Updated Clinical Data at the 2025 ASCO Gastrointestinal Cancers Symposium

AUSTIN, Texas and HAMILTON, ON and SAN DIEGO, Jan. 27, 2025 /PRNewswire/ -- Triumvira Immunologics, a clinical-stage company developing novel, targeted autologous and allogeneic T cell therapeutics that co-opt the natural biology of T cells to treat patients with solid tumors, recently presented an abstract at the 2025 American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium, which was held in San Francisco, California, from January 23-25, 2025. The company showcased updated clinical data from its ongoing Phase I/II TACTIC-3 study investigating the safety and efficacy of autologous TAC-T cells in subjects with Claudin 18.2+ advanced solid tumors (TACTIC-3 /NCT05862324). The poster presentation, titled "A Phase 1/2 Study Evaluating the Safety and Efficacy of Autologous TAC-T Cells in Subjects with Claudin 18.2+ Advanced Solid Tumors", provided an in-depth look at interim results from the Phase I study. Key highlights included: Patient Demographics and Characteristics: The study included subjects with multiple types of Claudin 18.2 positive advanced solid tumors, such as pancreatic, gastric, and esophageal cancers. . Safety Data: TAC01-CLDN18.2 demonstrated a favorable safety and tolerability profile. Two grade 3 events, gastritis and gastric hemorrhage, were observed in the same dose-level 3 (DL3) patient, and resolved within 4 days with supportive care. One Grade 1 immune-effector cell-associated neurotoxicity (ICAN) event resolved within 24 hours without intervention. Low-grade cytokine release syndrome (CRS) events were resolved with standard treatment. Preliminary Efficacy: Early clinical activity was observed, with a confirmed, ongoing partial response in a dose-level 1 (DL1) subject with stage IV pancreatic cancer, and an unconfirmed partial response in a heavily pretreated subject with esophageal adenocarcinoma (DL3). The disease control rate (DCR) was 70%, with an objective response rate (ORR) of 20% in a patient population that was not restricted based Claudin 18.2 expression levels, tumor burden, or location of metastatic disease. The TAC technology platform, exemplified by TAC01-CLDN18.2, reprograms T cells to co-opt the natural T cell receptor (TCR) signaling complex, providing precise tumor targeting and reduced systemic toxicity compared to conventional engineered T cell therapies. About Triumvira Immunologics Triumvira Immunologics, Inc. ("Triumvira") is a leading clinical-stage solid tumor cell therapy company developing unique, non-gene edited, first-in-class targeted autologous and allogeneic T cell therapeutics that co-opt the natural biology of T cells to treat patients with solid tumors. The company's proprietary T cell Antigen Coupler (TAC) technology platform activates natural T cell functions differently from other cell therapies such as CAR-T and engineered T cell receptor (TCR) therapies, resulting in clinically safe, effective, and re-dosable cell therapies. Triumvira is developing a pipeline targeting promising tumor-associated antigens such as Claudin 18.2, HER2, GUCY2C and GPC3. Triumvira has operations in San Diego, CA, Austin, Texas, and Hamilton, Ontario. For more information, visit us at or follow us on LinkedIn and X. Media Contact Ignacio Guerrero-Ros, Ph.D. Russo Partners 646-942-5604 [email protected] SOURCE Triumvira Immunologics WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

ImmunotherapyCell TherapyASCOPhase 1Clinical Result

100 Deals associated with Triumvira Immunologics, Inc.

100 Translational Medicine associated with Triumvira Immunologics, Inc.

Corporation Tree

Boost your research with our corporation tree data.

view full example data

Pipeline

Pipeline Snapshot as of 12 May 2025

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Preclinical

Phase 2 Clinical

Other

Current Projects

Drug(Targets)	Indications	Global Highest Phase

TAC-101 (Triumvira) ( CLDN18.2 )	NKG2DL Positive Solid Tumors More	Phase 2 Clinical
TAC100-HER2	Neoplasms More	Clinical
TAC-GPC3 ( GPC3 )	Liver Cancer More	Preclinical
GUCY2C-TAC T cells ( GC-C )	Colorectal Cancer More	Preclinical
TAC-201 (Triumvira) ( CLDN18.2 )	Pancreatic Ductal Adenocarcinoma More	Preclinical

Deal

Boost your decision using our deal data.

view full example data

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Profit

Explore the financial positions of over 360K organizations with Synapse.

view full example data

Grant & Funding(NIH)

Access more than 2 million grant and funding information to elevate your research journey.

view full example data

Investment

Gain insights on the latest company investments from start-ups to established corporations.

view full example data

Financing

Unearth financing trends to validate and advance investment opportunities.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis